Xenotransplantation Clinical Trials and Equitable Patient Selection
Bibliographic Data
| ID | 21598163 |
|---|---|
| Authors | Chris Bobier (0000-0003-4194-4721, Saint Mary's University of Minnesota, corresponding author), Daniel Rodger (0000-0002-2121-7167, London South Bank University) |
| Year | 2024 |
| Volume | 33 |
| Issue | 3 |
| Pages | 425-434 |
| Publication date | 2024-07-01 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Cambridge Quarterly of Healthcare Ethics (JOURNAL) |
| Journal identifiers | ISSN: 0963-1801 • E-ISSN: 1469-2147 |
| Publisher | Cambridge University Press (CUP) (PUBLISHER) |
| DOI | 10.1017/s096318012300052x |
| PMID | 37795637 |
| OpenAlex | W4387357563 |
| Language | EN |
| Citations received | 3 |
| References cited | 30 |
Xenotransplant patient selection recommendations restrict clinical trial participation to seriously ill patients for whom alternative therapies are unavailable or who will likely die while waiting for an allotransplant. Despite a scholarly consensus that this is advisable, we propose to examine this restriction. We offer three lines of criticism: (1) The risk–benefit calculation may well be unfavorable for seriously ill patients and society; (2) the guidelines conflict with criteria for equitable patient selection; and (3) the selection of seriously ill patients may compromise informed consent. We conclude by highlighting how the current guidance reveals a tension between the societal values of justice and beneficence
Clinical trial · Intensive care medicine · Xenotransplantation · Anesthesia and Neurotoxicity Research · Computer Science · Medicine · Organ Transplantation Techniques and Outcomes · Xenotransplantation and immune response · Artificial Intelligence · Internal Medicine · Transplantation
| Unique citing works | 3 |
|---|---|
| Citations per year | 3 |
| Citation span | 2025 - 2026 (2) |
| Citation velocity | current |
| Highly cited | No |
| Citation types | Neutral: 3 |